Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes

Breast Cancer

Volumn 16, Issue 4, 2009, Pages 301-306

  Tanabe, Masahiko ^a,b   Ito, Yoshinori ^a   Tokudome, Nahomi ^a   Sugihara, Tsutomu ^a   Miura, Hiroyoshi ^a   Takahashi, Shunji ^a   Seto, Yasuyuki ^b   Iwase, Takuji ^a   Hatake, Kiyohiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Anthracycline; Metastatic breast cancer; Methotrexate; Mitomycin C; Taxanes

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXIFLURIDINE; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; PACLITAXEL; STEROID; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; HEART PALPITATION; HEMATOLOGIC DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; LIVER METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROCYTOPENIA; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; METHOTREXATE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS;

EID: 70349671314     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0093-0     Document Type: Article

References (22)

1. R Fossati C Confalonieri V Torri E Ghislandi A Penna V Pistotti A Tinazzi A Liberati 1998 Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women J Clin Oncol 16 3439 60 9779724 1:CAS:528:DyaK1cXmvFGrurs%3D
2. AHG Paterson O Szafran F Cornish AW Lees J Hanson 1981 Effect of chemotherapy on survival in metastatic breast cancer Breast Cancer Res Treat 1 357 63 7348580 10.1007/BF01806751 1:STN:280:DyaL3s%2FnsF2gtg%3D%3D (Pubitemid 12011941)
3. RP A' Hern IE Smith SR Ebbs 1993 Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper-type regimens Br J Cancer 67 801 5
4. L Bignazoli T Cufer P Bruning R Coleman L Duchateau AH Calvert T Gamucci C Twelves P Fargeot R Epelbaum C Lohrisch MJ Picaart 2002 Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase Trial J Clin Oncol 20 3114 21 10.1200/JCO.2002.11.005 (Pubitemid 34791101)
5. GW Sledge D Neuberg P Bernardo JN Ingle S Martino EK Rowinsky WC Wood 2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 588 92 12586793 10.1200/JCO.2003.08.013 (Pubitemid 46621890)
6. J Sjostrom C Blomqvist H Mouridsen A Pluzanska S Ottosson-Lonn NO Bengtsson B Ostenstad I Mjaaland M Palm-Sjovall E Wist V Valvere H Anderson J Bergh 1999 Docetaxel compared with sequential methotrexate and fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group Eur J Cancer 35 1194 201 10615229 10.1016/S0959-8049(99)00122-7 1:CAS:528:DyaK1MXlvFWjur0%3D (Pubitemid 29359178)
7. A Morabito G Filippelli S Palmeri S Cascinu F Ferrau V Zagonel D Gattuso V Catalano B Capaccetti V Franciosi V Accurso F Scinto G Gasparini 2003 The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study Breast Cancer Res Treat 78 29 36 12611454 10.1023/A:1022197109592 1:CAS:528:DC%2BD3sXntV2rsQ%3D%3D (Pubitemid 36223014)
8. A Welt G Minckwitz C Oberhoff D Borquez R Schleucher S Loibl A Harstrick M Kaufmann S Seeber U Vanhoefer 2005 Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer Ann Oncol 16 64 9 15598940 10.1093/annonc/mdi024 1:STN:280:DC%2BD2cnitlWjsA%3D%3D (Pubitemid 40124480)
9. V Lorusso M Spada M Giampaglia A Misino R Calabrese A Latorre G Monticelli M Guida D Sambiasi G Colucci 2006 Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale) Ann Oncol 17 suppl 7 vii15 7 16760280 10.1093/annonc/mdl942 (Pubitemid 43985171)
10. GN Hortobagyi 1993 Mitomycin: its evolving role in the treatment of breast cancer Oncology 50 suppl 1 1 8 8483556 10.1159/000227240
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an over view of the randomised trials Lancet 365 1687 717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
12. JA Mabel I Wodinsky 1983 Mitomycin C combination therapy against murine tumor systems Cancer 51 600 5 6401590 10.1002/1097-0142(19830215)51:4<600:: AID-CNCR2820510408>3.0.CO;2-C 1:STN:280:DyaL3s7gt1Omtw%3D%3D
13. IE Smith TJ Powles 1993 MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer Oncology 50 suppl 1 9 15 8483562 10.1159/000227241
14. General rules for clinical and pathological recording of breast cancer 1989 The Japanese breast cancer society, 13th and 14th edition Jpn J Surg 19 5 612 32 10.1007/BF02471672 (Pubitemid 20044125)
15. P Therasse SG Arbuck EA Eisenhaur J Wanders RS Kaplan L Rubinstein J Verweij MV Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 3 205 16 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
16. RH Creech RB Cataland MK Shah H Dayal 1983 An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer Cancer 51 1034 40 6821868 10.1002/1097-0142(19830315) 51:6<1034::AID-CNCR2820510611>3.0.CO;2-B 1:STN:280:DyaL3s7gt1yhsg%3D%3D (Pubitemid 13158793)
17. RB Pasterz AU Buzdar GN Hortobagyi GR Blumenschein 1985 Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy Cancer 56 2381 4 4042070 10.1002/1097-0142(19851115)56:10<2381::AID- CNCR2820561006>3.0.CO;2-2 1:STN:280:DyaL28%2Fgt1WnsQ%3D%3D (Pubitemid 16202428)
18. A Urruticoechea CD Archer LA Assersohn RK Gregory M Verrill R Mendes G Walsh IE Smith SRD Johnston 2005 Mitomycin C, vinblastin and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer Br J Cancer 92 475 9 15685237 1:CAS:528:DC%2BD2MXhtFWnt7s%3D
19. JM Nabholtz HJ Senn WR Bezwoda D Melnychuk L Deschens J Douma TA Vandenberg B Rapoport R Rosso V Trillet-Lenoir J Drbal A Molino JWR Nortier DJ Richel T Nagykalnai P Siedlecki N Wilking JY Genot PSGJ Hupperts F Pannuti D Skarlos EM Tomiak M Murawsky M Alaki A Riva Aapro M for the 304 study group 1999 Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy J Clin Oncol 17 1413 24 10334526 1:CAS:528:DyaK1MXjsF2msrc%3D
20. C Massacesi AL Cesa F Marcucci A Pilone MBL Rocchi L Zepponi D Santini G Tonini L Burattini 2006 Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer Oncology 70 294 300 17047400 10.1159/000096250 1:CAS:528:DC%2BD28XhtFGjs7vM (Pubitemid 44670171)
21. JE Cantrell TM Phillips PS Schein 1985 Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy J Clin Oncol 3 723 34 3923162
22. J Verweij T van Zanten T Souren R Golding M Pinedo 1987 Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonaitis Cancer 60 756 61 3109726 10.1002/1097-0142(19870815)60:4<756::AID- CNCR2820600408>3.0.CO;2-H 1:STN:280:DyaL2s3ktl2nsA%3D%3D